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Interleukin 4 (X4) has been shown to exhibit anti-inflammatory effects by inhibiting the secretion by monocytes of proinflammatory cytokines 
such as interleukin 1 (ILl), interleukin 6 (IL6), and tumor necrosis factor (TNF) and by inducing the secretion of the IL1 receptor antagonist. We 
investigated the role of this cytokine on the production of acute-phase proteins in primary human hepatocyte cultures. Cells were. exposed to either 
IL4 and/or IL6, the most potent mediator of hepatic acute phase proteins. IL4 led to decreased production of haptoglobin, C-reactive protein and 
albumin while ccl-antitrypsin and fibrinogen remained unaffected. These inhibitory effects of IL4 were also observed at the mRNA level. In addition, 
IL4 inhibited the IL6-induced production of haptoglobin although it had no effect on the induced C-reactive protein and fibrinogen. Our results 
demonstrate that IL4 can affect the production of a subset of acute-phase proteins by human hepatocytes and can antagonize some of the effects 
of IL6. These observations reinforce the notion that IL4 can be considered as an anti-inflammatory cytokine. 
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1. INTRODUCTION 
The acute-phase response is characterized by a set of 
hepatic disturbances which include marked variations 
in the concentration of some plasma proteins [l-4], im- 
pairment of drug metabolism [5,6] and alterations of 
lipid metabolism [7J. 
Acute-phase protein patterns vary from one species 
to another. Thus, C-reactive protein (CRP) and serum 
amyloid A show the highest increase in man [8] whereas 
in the rat, c+macroglobulin and q-acid glycoprotein 
exhibit the most substantial increases. In many species, 
plasma concentrations of fibrinogen, a,-antitrypsin, 
haptoglobin and a,-anti-chymotrypsin also increase 
and, simultaneously, albumin and transferrin plasma 
levels decrease [1,9-l 31. 
The acute-phase response is mediated by cytokines 
[ 141, six of which have been reported to modify produc- 
tion of plasma proteins by the hepatocyte. The most 
potent mediators are IL6 [8-10,13,15], interleukin- 1 
(ILl) [ 131 and tumor necrosis factor cz (TNFa) [13]. IL6 
induces the broadest range of proteins [15]. By contrast, 
interferon y (IFNr) down-regulates only a few proteins 
[l]. Two additional cytokines, i.e. leukemia inhibitory 
factor (LIF) [16] and transforming growth factor /3 
(TGFB) are now recognized to be capable of modulat- 
ing production of acute-phase proteins [17-201. How- 
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ever, it has now become apparent hat changes in many 
hepatic plasma proteins during the acute-phase re- 
sponse are not mediated by a single cytokine but rather 
by a combination of cytokines [19]. 
Interleukin 4 (IL4) produced by T lymphocytes [21] 
and mast cells [22], displays a wide range of biological 
effects [23,24] as suggested by the expression of its spe- 
cific receptor in nearly all the cell types [25,26]. Up to 
now, the effects of IL4 on the production of acute-phase 
proteins by hepatocytes have not been studied. The only 
effect reported on hepatic cells, is the inhibition of the 
lipogenesis timulation by ILl, IL6 and TNFa in mouse 
hepatocytes [27]. These effects as well as the inhibition 
of IL 1, TNFa, prostaglandin E2 [28,29] and stimulation 
of IL1 receptor antagonist (ILlra) production by IL4 
in human monocytes [30], suggest hat IL4 could act as 
an anti-inflammatory mediator. This led us to investi- 
gate whether other liver functions, including production 
of plasma proteins that are increased during acute- 
phase response, could be modulated by IL4. In the pres- 
ent report, we show that IL4 can affect the production 
of various plasma proteins in human hepatocytes and 
negatively regulate some of the effects induced by IL6. 
2. MATERIALS AND METHODS 
2.1. Materials 
Cell culture reagents were purchased from Gibco (Cergy-Pontoise, 
France). Recombinant human IL4 (specific activity: 10’ U/ml) was 
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provided by Schering-Plough Research Institute (Kenilworth, NJ). 
Purified recombinant human IL6 used was provided by Genzyme 
(Cambridge, UK) and used at 50 U/ml. Semi-purified IL6 obtained 
from transfected COS cells, was also used in some experiments. When 
tested in parallel, both purified- and semi-purified IL6 batches gave 
similar quantitative results (not shown). 
Antisera from rabbit anti-CRP, anti-haptoglobin, anti-a,-antitryp- 
sin and anti-fibrinogen were from Hoechst-Behring (France), goat 
anti-CRP and anti-haptoglobin from Calbiochem and rabbit anti- 
albumin from Cappel (USA). 
The human albumin and p-fibrinogen cDNAs were gifts from A. 
Dugaiczyk and G. Marguerie, respectively. cDNA probes for hapto- 
globin, CRP and cc,-antitrypsin were purchased from the American 
Type Culture Collection (ATCC, Rockville, USA). 5’-[&-32P]tri- 
phosphate deoxycytidine (3000 Ciimmol) was from Amersham (Les 
Ulis, France). 
2.2. Cell cultures 
Human hepatic tissue biopsies were obtained from seven donors 
(HLI-7) in agreement with French legislation. The group of donors 
was composed of three females (HLl = 53, HL3 = 41 and HL5 = 73 
years old) and four males (HL2 = 46, HI.4 = 64, HL6 = 52 and 
HL7 = 50 years old). Hepatocytes were isolated by a two-step collage- 
nase perfusion procedure as previously described [32]. The average cell 
viability was 81 + 6%. Hepatocytes were seeded at 1.5 x lo5 cells/well 
in 24 multi-well plates for protein concentration determination, or at 
10’ cells/75 cm’ flask for total RNA preparation, in a mixture of 75% 
minimum essential medium and 25% medium 199, supplemented with 
10% fetal calf serum and, per ml: 100 IU penicillin, 100 pg streptomy- 
cin sulphate, 1 mg bovine serum albumin and 5 rug bovine insulin. 
After cell attachment (e.g. around 10 h later), the medium was renewed 
with the same medium deprived of fetal calf serum and supplemented 
with 7 x 10e5 M hydrocortisone hemisuccinate. At this time, the cytok- 
ines were added and it was changed every day thereafter. Conditioned 
media were collected and frozen prior to determination of plasma 
protein concentrations. 
2.3. ELISA assays 
Concentration of CRP and haptoglobin in culture medium was 
determined by a sandwich enzyme immunoassay (ELISA). 96-well 
microtiter plates were coated with goat anti-CRP or anti-haptoglobin 
antibodies diluted to 112500 and 112000, respectively, in0.1 M carbon- 
ate buffer, pH 9.6, for 18 h at 4°C. Wells were then washed two times 
with phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween 
20. Blocking was performed for 60 min at room temperature with PBS 
containing 3% (w/v) bovine serum albumin. After washes, standards 
or samples were added to the wells, followed by an 18 h incubation 
at 4OC. After three PBS-Tween washes, rabbit antibodies against CRP 
(11750 dilution in PBS-Tween) or against haptoglobin (111000 dilu- 
tion) were added and incubated for 120 min at 37’C. After three 
washes, the wells were incubated with peroxidase-conjugated anti- 
rabbit IgG (Sigma, l/25000 dilution in PBS-Tween) for 60 min at 
37°C. Plates were washed three times with PBS-Tween and 100 ~1 of 
the peroxidase substrate solution (citrate-phosphate buffer, pH 5.0, 
containing 0.4 mg of O-phenylendiaminelml and 0.01% H,O,, v/v) 
were added to each well. Color development was stopped by the 
addition of 50 ~1 of 2.5 M sulfuric acid and plates were read at 492 
nm using a microplate photometer (Titertek Multiscan MCC1340, 
Labsystems, Finland). Standards for the determination of CRP and 
haptoglobin levels, N/T CRP control serum and N/T protein standard 
serum were from Behring. 
2.4. Immunonephelometry 
Albumin, a,-antitrypsin and fibrinogen production was quantified 
in the culture medium by laser immunonephelometry [33]. The validity 
of this method was confirmed by the linearity of the reference curve 
obtained by addition to the medium of increasing amounts of stan- 
dards. Results were expressed as &ml/24 h. 
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2.5. Statistical analysis 
Values (as percent of variation with the corresponding control 
value), were analysed by Student’s t-test, and the criterion for signifi- 
cance of the differences between IL4- or IL6-treated cultures versus 
controls was P < 0.05. 
2.6. RNA analysis 
Total RNAs were extracted by the guanidium thiocyanate proce- 
dure [34] and quantified. For each sample, 2 pug of total RNA were 
subjected to electrophoresis and stained with ethidium bromide to 
check quality and quantification of the RNAs. For dot blot hybridiia- 
tion, aliquots of 10 and 5 pg RNA were spotted onto nylon N’ 
membrane (Amersham) that had been pretreated with 20 x standard 
saline citrate. For Northern blot analysis, 20 pg of total RNA were 
separated by electrophoresis in 1.5% agarose gels, in 10 mM phos- 
phate buffer, pH 7.4 containing 1 .l M formaldehyde and then trans- 
ferred onto nylon N+ membranes. RNA amounts in each lane and 
transfer efficiency were verified by staining the gel with ethidium 
bromide. The Northern and dot blots were prehybridized according 
to Andrews et al. [35]. Hybridizations with 20 to 25 x lo6 cpm/mem- 
brane of [a-“‘P]dCTP nick-translated DNA probes were carried out 
for 18 h. Post-hybridization washes were performed at 65’C in 1 x 
standard saline citrate, 0.1% SDS. Filters were autoradiographied 
using hyperfilms MP (Amersham, UK) with DuPont lightning Plus 
intensifying screens at -80” C. 
3. RESULTS 
The effect of IL4 on haptoglobin production was 
investigated in human hepatocyte primary cultures in- 
cubated with various concentrations of the cytokine 
ranging from 1 to 150 U/ml for 4 days (Fig. 1). Hepato- 
cyte cultures were also exposed to IL6 (50 U/ml) which 
stimulatory effect on the production of acute phase pro- 
tein is well known. The medium was totally renewed 
every day and the levels of proteins were measured in 
the culture supernatants harvested daily. After three 
haploglobin 
6 
control 1 2.5 5 50 160 60 
IL4 -iii7 
Concentrations (U/ml) 
Fig. 1. Dose-response of haptoglobin production to IL4 exposure. IL4 
was added daily during 3 days, at 1, 2.5, 5, 50 and 150 U/ml to 
determine dose-response ffects on haptoglobin level at day 3. IL6 was 
added daily at 50 U/ml. The values are the mean +- S.D. (bars) of four 
dishes, and are expressed as &ml/24 h. 
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Fig. 2. Time-course analysis of the effects of ILA and IL6 on hapto- 
globin and C-reactive protein production. Hepatocytcs were treated 
10 h after plating with IL4 (50 U/ml) or IL6 (50 U/ml) and daily 
thereafter during 4 days. The 24 h-conditioned media from control, 
II.& and IL&cdtures were collected during the 4 days and used for 
determination of haptoglobin and C-reactive protein production rates. 
days of treatment, haptoglobin secretion was decreased 
by IL4 in a dose-dependent manner; in contrast, it was 
increased by IL6. IL4 had a maximal inhibitory effect 
(60%; mean of 2 experiments) on haptoglobin secretion 
when used at a concentration of 50 U/ml and above. No 
significant difference was observed with a higher con- 
centration (i.e. 150 Wml). Consequently, IL4 was used 
at 50 U/ml for further experiments. 
The kinetics of the modulatory effects of IL4 (50 
U/ml) and IL6 on haptoglobin and CRP production 
were then studied during a 4-day culture (Fig. 2). IL6 
did not modify haptoglobin production during the first 
24 h, and only slightly increased it after 48 h. The secre- 
tion of haptoglobin was markedly augmented (2 to 3- 
fold) by IL6 after 72 and 96 h. IL6 also increased CRP 
production, whatever the culture time. However, IL6 
did not prevent the decrease at 48, 72 and 96 h (< 0.1 
,~$nl/24 h). Haptoglobin and CRP production were 
both slightly don-reg~ated by IL4 during the first 
day. IL4 had a strong debiting effect on the produc- 
tion of these two proteins after 72 h. The decreased 
production could still be observed at day 4 with hapto- 
globin but not with CRP which secretion was virtually 
abolished at that time. 
Hepatocytes from seven different donors were incu- 
bated with IL4 and IL6 for 3 days, and the secretion of 
albumin, fibrinogen and a,-antitrypsin was compared 
with that of haptoglobin and CRP. The effects meas- 
ured at day 3 are presented in Table I. IL6, used as a 
reference mediator, induced a typical response charac- 
terized by an increased level of hapto~obin, fibrinogen, 
CRP and ai-antitrypsin, and a depressed production of 
albumin. The strongest effect was observed for fibrino- 
gen, the concentration of which reached 5-fold the con- 
trol value after a 3&y exposure. A 30% decreased se- 
cretion of albumin was found after 72 h. IL4 did not 
alter production of fibrinogen and a,-antitrypsin, 
whereas it depressed haptoglobin and CRP. Surpris- 
ingly, IL4 decreased the production of albumin as much 
as did IL6. 
The effects of IL6 and IL4 on the expression of hap- 
toglobin, albumin, ~-fibrinogen and ~~-anti~sin were 
also analysed at mRNA levels by dot blotting using 
specific cDNA probes (Fig. 3A). Total mRNA was ex- 
tracted from hepatocytes cultured for 4 days with IL6 
or IL4 and probed successively with the different spe- 
cific cDNAs. In IL6-treated cells, mRNA levels of ,& 
~b~nogen, ~,-antit~sin and haptoglobin were in- 
creased by 9-, 4- and 5-fold, respectively, while the albu- 
min mRNA level dropped to 10% of the control value. 
Albumin and haptoglobin mRNA levels were de- 
creased, respectively 2- and 3-fold by IL4 treatment (50 
U/ml), whereas ~-fib~nogen and ~~-antit~sin mRNA 
levels were unaffected. 
The decrease of CRP protein observed from 48 h of 
culture, was also found at the mRNA level but after 
three or four days CRP mRNAs were only detectable 
as very faint bands which did not permit accurate com- 
parisons (not shown). Thus, the effects of IL6 and IL4 
on CRP transcripts were evaluated by Northern-blot 
analysis after a 24 h treatment (Fig. 3B). A marked 
increase of CRP mRNA was observed in 24 h control 
cultured ceils compared to their freshly isolated coun- 
terparts. This increase was transient and CRP mRNA 
became undetectable in 72 and 96 h control cultures 
(not shown). After 24 h of treatment, the levels of CRP 
mRNA were increased by IL6 and decreased by IL4. 
Thereafter, the membrane was hybridized with hapto- 
globin cDNA probe and variations of haptoglobin 
mRNA levels were compared to those observed for 
CRP. No early induction of haptoglobin mRNA was 
observed when isolated hepatocytes were placed in cul- 
ture. A 24 h exposure to IL4 considerably reduced hap- 
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Alb 
Fib 
Fig. 3. Effects of IL4 and IL6 on levels of haptoglobin, albumin, B-fibrinogen, a,-antitrypsin and C-reactive protein mRNAs. (A) After 96 h of 
culture, total RNA was isolated in control (lane 1), IL4 (5 and 50 U/ml, lanes 2 and 3), and IL6 (recombinant semi-purified cytokine, lane 4)-treated 
cultures and subjected to dot blot analysis (10 and 5 pg) with haptoglobin (Hpt), albumin (Alb), fibrinogen (Fib), and a,-antitrypsin (Aat) specific 
cDNA probes. (B) Northern blot analysis of CRP and haptoglobin (Hpt) mRNA levels in freshly isolated hepatocytes (lane 1), and in 24 h control 
cultures (lane 2), IL4 (50 U/ml, lane 3) and IL6 (50 U/ml, lane 4)-treated cultures. 
toglobin mRNA levels. In contrast, incubation with IL6 
increased them. 
In order to better define the potential role of IL4 
during the acute phase response, the effects of IL4 on 
IL6-stimulated hepatocytes were investigated in two ex- 
periments. Hepatocyte cultures were exposed to a single 
dose of IL6 (50 U/ml) or IL4 (50 U/ml) or simultane- 
ously treated with both IL6 and IL4 (50 U/ml each) and 
the levels of CRP, fibrinogen and haptoglobin were 
measured after 2 and 3 days of exposure (Fig. 4). As 
observed in Fig. 2, treatment by IL4 decreased hapto- 
globin while IL6 stimulation triggered overexpression 
of this protein. Simultaneous treatment with IL6 and 
IL4 resulted in a complete inhibition of haptoglobin 
induction by IL6 (P < 0.05). In contrast, IL4 did not 
affect stimulation of CRP and fibrinogen production by 
IL6 (not shown). 
4. DISCUSSION 
In the present study, using primary cultures of nor- 
ma1 human hepatocytes, we confirmed that IL6 acts as 
Table I 
Haptoglobin, albumin, C-reactive protein, fibrinogen and cc,-antitrypsin concentrations in human hepatocyte cultures treated with IL4 or IL6 
IL4 IL6 
Mean % S.D. (8) range (%) n P Mean 8 S.D. (8) Range (%) n P 






45 16 25569 26* 0.0013 185 43 15@287 26* 0.0001 
7t 7’ 
71 3.1 67-74 20* 0.001 69.7 5 63-75 20* 0.0001 
s 5f 
54 20 42-78 13* 0.001 275 50 22&400 9* 0.0001 
3f 3’ 
120 43 8&150 12* 0.055 506 260 22&725 12* 0.005 
3f 3t 
104 9 90-113 12: 0.33 263 37 244470 8* 0.0001 
3’ 3’ 
Results are the average of tetraplicate (n = 4) cultures of independent experiments and expressed as percent of variation (mean f S.D.) from the 
corresponding control value average (100%). IL4 (50 U/ml) and IL6 (50 U/ml) or semi-purified) were used and plasma protein levels were determined 
at day 3. The values which composed these different averages were analysed by the Student’s r-test, and the criterion for significance of the differences 
between control and treated cultures was P c 0.05; n: *number of independent protein concentration determinations, $number of independent 
cultures; Range: minimal and maximal percent of variation vs. control (100%). 
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Fig. 4. IL4 effect on haptoglobin stimulation induced by IL6. Hapto- 
globin concentrations were determined in control. IL4 (50 U/ml), IL6 
(semi-purified) and IL6 + ILA-treated (50 U/ml) cultures. Values are 
expressed as &ml/24 h, are the mean t S.D. (bars) of two independ- 
ent experiments in tetraplicate and were analysed by Student’s t-test. 
*P < 0.05 IL4 or IL6 vs. control; **P < 0.05 IL6 + IL4 vs. IL6. 
a very potent mediator of the hepatic acute phase re- 
sponse. The stimulation of fibrinogen, CRP, hapto- 
globin and cq-antitrypsin by IL6 found in human hepa- 
tocytes demonstrated that these cells retained in vitro 
the capacity to respond to inflammatory mediators. 
More importantly, we demonstrated that IL4 can also 
affect the production by hepatocytes of some acute- 
phase proteins. IL4 inhibited the production of three of 
the five acute-phase proteins studied, i.e. haptoglobin, 
CRP and the negative acute-phase protein albumin. 
These effects were shown both at mRNA and protein 
levels. 
The selectivity of IL4 effect on the production of only 
some proteins as well as the absence of general altera- 
tion of the total protein content and cell morphology, 
allow us to eliminate the possibility of a toxic effect of 
IL4 on hepatocytes. In addition, in a parallel study, we 
have recently shown that IL4 is also able to markedly 
affect cytochrome P450 expression in cultured human 
hepatocytes [31]. To our knowledge, this is the first 
evidence that IL4 can affect hepatic functions in hu- 
mans. 
Our findings also show that CRP, the most induced 
acute phase protein in man, was strongly enhanced fol- 
lowing hepatocyte seeding while fibrinogen, hapto- 
globin and a,-antitrypsin were not altered. The tran- 
sient increase in CRP, also reported by Moshage et al. 
[12], appears to be related to the dissociation process 
and the adaptation of human hepatocytes to culture. 
Potential anti-inflammatory effects of IL4 have been 
shown previously. Indeed, IL4 has been shown to in- 
hibit production of ILl, TNFa and prostaglandin E2 
[28,29] and to induce IL1 receptor antagonist secretion 
[30] by human monocytes. Grunfeld et al. [27] have 
confirmed that IL4 acts as anti-inflammatory mediator 
since it was able to inhibit stimulation by TNF&, IL1 
and IL6, of hepatic lipogenesis in mouse in vivo. How- 
ever, they did not observe any effect of IL4 by itself on 
lipogenesis. Our data show that IL4 can decrease hap- 
toglobin, CRP and albumin production regardless of 
stimulation by recombinant IL6, and can modulate IL6- 
mediated induction of haptoglobin. Moreover, we have 
not shown by ELISA, the presence of endogenous IL6 
(not shown), strongly suggesting that the effects of IL4 
on haptoglobin, CRP and albumin are direct and not 
due to modulation of an endogenous ILb-response. 
The fact that IL4 is able to act on negative (albumin) 
as well as on positive (CRP, haptoglobin) acute-phase 
proteins, and to antagonize some effects of IL6, leads 
us to consider IL4 as a modulator of hepatic plasma 
protein production and support the idea of its anti- 
inflammatory function. The data collected on the IL4 
function raise the possibility that this cytokine (1) could 
be produced by liver-associated lymphocytes including 
large granular (i.e. Pit cells) and agranular lymphocytes 
[37,38], since these cells display natural killer and lym- 
phokine-activated killer activities [38]; (2) could act on 
other hepatic functions (including plasma proteins and 
cytochrome P450 enzymes) and may antagonize and/or 
cooperate with other cytokines; (3) could be involved in 
the development of some liver diseases. Indeed, Schlaak 
et al. [39] have recently reported elevated IL4 produc- 
tion by liver infiltrating T cells in autoimmune hepatitis. 
Thus, it would be extremely important to determine 
whether lymphocytes located in normal and pathologic 
livers, produce IL4 and what is the incidence of this 
production on hepatic functions. 
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